269 related articles for article (PubMed ID: 30601909)
1. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review.
Navarrete-Dechent C; Mori S; Barker CA; Dickson MA; Nehal KS
JAMA Dermatol; 2019 Mar; 155(3):361-369. PubMed ID: 30601909
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
3. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
[TBL] [Abstract][Full Text] [Related]
4. From Morphea to Dermatofibrosarcoma Protuberans.
Crnarić I; Šitum M; Delaš Aždajić M; Vučić M; Buljan M
Acta Dermatovenerol Croat; 2022 Sep; 30(2):113-115. PubMed ID: 36254545
[TBL] [Abstract][Full Text] [Related]
5. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).
Stacchiotti S; Pantaleo MA; Negri T; Astolfi A; Tazzari M; Dagrada GP; Urbini M; Indio V; Maestro R; Gronchi A; Fiore M; Dei Tos AP; Conca E; Palassini E; Vincenzi B; Grosso F; Pilotti S; Castelli C; Casali PG
Clin Cancer Res; 2016 Feb; 22(4):837-46. PubMed ID: 26261104
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.
Kambayashi Y; Kasahara Y; Ohuchi K; Amagai R; Hashimoto A; Asano Y; Fujimura T
Dermatol Ther; 2022 Oct; 35(10):e15736. PubMed ID: 35898161
[TBL] [Abstract][Full Text] [Related]
11. Dermatofibrosarcoma protuberans: recent clinical progress.
McArthur G
Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
Rutkowski P; Van Glabbeke M; Rankin CJ; Ruka W; Rubin BP; Debiec-Rychter M; Lazar A; Gelderblom H; Sciot R; Lopez-Terrada D; Hohenberger P; van Oosterom AT; Schuetze SM; ;
J Clin Oncol; 2010 Apr; 28(10):1772-9. PubMed ID: 20194851
[TBL] [Abstract][Full Text] [Related]
13. [Dermatofibrosarcoma protuberans].
Sanmartín O; Llombart B; López-Guerrero JA; Serra C; Requena C; Guillén C
Actas Dermosifiliogr; 2007 Mar; 98(2):77-87. PubMed ID: 17397592
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases.
Tatai T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Koizumi T; Sano K
Intern Med; 2016; 55(17):2507-11. PubMed ID: 27580559
[TBL] [Abstract][Full Text] [Related]
15. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
Johnson-Jahangir H; Sherman W; Ratner D
J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
[TBL] [Abstract][Full Text] [Related]
16. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change.
Liang CA; Jambusaria-Pahlajani A; Karia PS; Elenitsas R; Zhang PD; Schmults CD
J Am Acad Dermatol; 2014 Oct; 71(4):781-6. PubMed ID: 24755121
[TBL] [Abstract][Full Text] [Related]
18. Dermatofibrosarcoma protuberans - the use of neoadjuvant imatinib for treatment of an uncommon breast malignancy: a case report.
McGee MW; Boukhar SA; Monga V; Weigel R; Phadke SD
J Med Case Rep; 2019 Dec; 13(1):374. PubMed ID: 31852518
[TBL] [Abstract][Full Text] [Related]
19. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans.
Delyon J; Porcher R; Battistella M; Meyer N; Adamski H; Bertucci F; Guillot B; Jouary T; Leccia MT; Dalac S; Mortier L; Ghrieb Z; Da Meda L; Vicaut E; Pedeutour F; Mourah S; Lebbe C
J Invest Dermatol; 2021 Apr; 141(4):761-769.e2. PubMed ID: 32956651
[TBL] [Abstract][Full Text] [Related]
20. Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.
Wicherts DA; van Coevorden F; Klomp HM; van Huizum MA; Kerst JM; Haas RL; van Boven HH; van der Hage JA
World J Surg Oncol; 2013 Mar; 11():59. PubMed ID: 23496933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]